Back to top
more

Sarepta Therapeutics (SRPT)

(Delayed Data from NSDQ)

$17.53 USD

17.53
5,608,806

+0.57 (3.36%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $17.55 +0.02 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Nalak Das headshot

5 Mid-Cap Stocks to Buy in a Volatile January

by Nalak Das

We have narrowed our search to five mid-caps that have strong potential for 2024. These are: DVA, MNDY, GTLB, LNW, SRPT.

Zacks Equity Research

GSK to Buy Private Biotech, Strengthen Respiratory Pipeline

by Zacks Equity Research

GSK's proposed acquisition of Aiolos is set to add the latter's long-acting anti-TSLP monoclonal antibody, AIO-001, to GSK's broad portfolio of respiratory products.

Zacks Equity Research

Sarepta Therapeutics (SRPT) Surges 16.7%: Is This an Indication of Further Gains?

by Zacks Equity Research

Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks Equity Research

Sarepta (SRPT) Rises on Solid Q4 and 2023 Preliminary Results

by Zacks Equity Research

Sarepta (SRPT) issues encouraging preliminary results for the fourth quarter and full-year 2023. Shares of the company rise.

Zacks Equity Research

Vericel Corporation (VCEL) Moves 7.0% Higher: Will This Strength Last?

by Zacks Equity Research

Vericel Corporation (VCEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Amicus (FOLD) Issues Preliminary Revenue Results for FY23

by Zacks Equity Research

Amicus (FOLD) posts preliminary results for full-year 2023. The company also provides a strategic outlook for 2024.

Zacks Equity Research

Allogene (ALLO) Down 20% on Strategic Changes in Pipeline

by Zacks Equity Research

Allogene (ALLO) decides to deprioritize two pivotal studies for the third-line treatment of certain lymphoma patients and start a new study to focus on the first-line treatment of the indication.

Ekta Bagri headshot

3 Top Biotech Stocks Worth Adding to Your Portfolio in 2024

by Ekta Bagri

REGN, BGNE & SRPT are three biotech companies that are likely to outperform the sector on the back of strong fundamentals.

Zacks Equity Research

Esperion (ESPR) Settles Milestone Dispute With Daiichi Sankyo

by Zacks Equity Research

Daiichi Sankyo amends its existing collaboration with Esperion (ESPR), including the resolution of a commercial dispute over milestone payments. This amendment is valued at $125 million.

Zacks Equity Research

Wall Street Analysts Believe Sarepta Therapeutics (SRPT) Could Rally 50.54%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at a 50.5% upside potential for Sarepta Therapeutics (SRPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.